• 2026.10.05Timely Disclosure
  Completion of Patient Enrollment in an Investigator-Initiated Phase III Clinical Trial of Nivolumab in Combination with the PAI-1 Inhibitor RS5614 for Unresectable Malignant Melanoma(417KB)
• 2026.09.29Timely Disclosure
  Notice of Completion of Patient Dosing in a Phase III Trial of PAI-1 Inhibitor RS5614 in Combination with Tyrosine Kinase Inhibitors (TKIs) for Chronic Myeloid Leukemia(473KB)
• 2026.09.25Timely Disclosure
  Announcement of Orphan Drug Designation for Cutaneous Angiosarcoma(171KB)
• 2026.08.14Financial Statements
  Non-consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)(169KB)
• 2026.08.12Timely Disclosure
  Notice Regarding Withdrawal from XPRIZE Healthspan(371KB)

IR News List